A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics based on the inhibition of restriction endonuclease BamHI.
AUTOR(ES)
Puvvada, M S
RESUMO
An assay has been developed (restriction endonuclease digestion assay--RED100) based on inhibition of the restriction endonuclease BamHI that is capable of quantitative evaluation of the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics. This method provides comparable results to those obtained from thermal denaturation and ethidium bromide displacement assays but is much more sensitive, discriminating between molecules of similar structure such as DC-81, iso-DC-81 and neothramycin. The results reveal a trend between relative DNA-binding affinity and in vitro cytotoxicity for the PBDs in two tumour cell lines studied.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=309864Documentos Relacionados
- Cloning the BamHI restriction modification system.
- Overexpression, purification and crystallization of BamHI endonuclease.
- A polymorphism of the human von Willebrand factor (vWf) gene with BamHI.
- Sequence-specific endonuclease BamHI: relaxation of sequence recognition.
- Direct selection of binding proficient/catalytic deficient variants of BamHI endonuclease.
